717 / 1082
S701
ESTRO 36 2017
_______________________________________________________________________________________________
Conclusion
A combination of
radical and “adjuvant” radiotherapy in
prostate cancer patients with synchronous oligometastatic
bony disease at diagnosis and surgically managed show
promising results in terms of both biochemical control and
distant progression-free survival. The only severe event
was probably caused by a previously used
hypofractionated protocol for prostatic bed irradiation
that was abandoned in 2013.
EP-1320 Phase II Study of SBRT as Treatment for
Oligometastases in Prostate Cancer: Trial in progress.
A. Conde Moreno (Spain), J. Lopez Torrecilla, J. Pastor
Peidro, A. Hervás Morón, F. López-Campos, A. Mendez
Villamón, M.M. Puertas Valiño, A. Sola Galarza, M. Rico
Oses, P. Samper Ots, L.A. Pérez-Romasanta, C. Ibañez
Villaoslada, J. Valero Albarrán, N. Ortiz Rodil, F. García
Piñon, C. Ferrer Albiach
1
Consorcio Hosptialario Provincial de Castellon,
RADIATION ONCOLOGY, Castellon, Spain
2
Eresa Hospital General De Valencia, RADIATION
ONCOLOGY, VALENCIA, Spain
3
Hospital Ramón y Cajal, RADIATION ONCOLOGY,
MADRID, Spain
4
Hospital Universitario Miguel Servet, RADIATION
ONCOLOGY, ZARAGOZA, Spain
5
Complejo Hospitalario De Navarra, RADIATION
ONCOLOGY, PAMPLONA, Spain
6
Hospital Rey Juan Carlos, RADIATION ONCOLOGY,
MOSTOLES, Spain
7
Hospital Clínico De Salamanca, RADIATION ONCOLOGY,
SALAMANCA, Spain
8
Hospital Central De La Defensa Gómez Ulla, RADIATION
ONCOLOGY, MADRID, Spain
9
Hospital Universitario Sanchinarro Grupo HM,
RADIATION ONCOLOGY, MADRID, Spain
10
Consorcio Hospitalario Provincial de Castellón,
RADIATION ONCOLOGY, CASTELLON, Spain
11
Fundación Hospital Provincial, BIOSTATISTICS,
CASTELLON, Spain
Purpose or Objective
SBRT-SG 05 (ClinicalTrials.gov NCT02192788 ) is a
collaborative (SBRT-SG, GICOR and SEOR) phase II trial
testing SBRT and hormonotherapy in oligometastatic
prostate cancer patients. The aim of this study is to
determine response, and biochemical control rates,
progression free survival, chemotherapy free survival and
impact of treatment on quality of life. We describe here
the protocol and first results. This type of studies are
currently on the rise worldwide representing interest for
this kind of approach.
Material and Methods
Patients with histologically confirmed prostate cancer
(hormone-sensitive or castration-resistant) in an
oligorrecurrent stage after primary treatment for their
disease were assigned to receive SBRT (Vertebral
Metastases: 1x16-18Gy or 3x8-9Gy. Lymph node
Metastases: 3x10-11 Gy or 6x7,5Gy. Non-spinal bone
metastases: 1x16Gy or 3x10Gy). Medical treatment could
include LHRH analogues or antiandrogens. The following
Inclusion Criteria were established: Time to biochemical
recurrence more than 1 year; PSA doubling time> 2
months; Less than 5 bone or lymph node metastases
(including spinal) by Choline PET-CT or / and WB-DWI-MRI.
To ensure homogeneity in the sample, all patients should
have hormone therapy according to current
recommendations planning its withdrawal within two
years after treatment if biochemical control has been
achieved. The percentage of castration resistance
patients will be at most 30% and at least 10%of the sample.
Concomitant treatment with chemotherapy, abiraterone
or enzalutamide is not allowed.
Results
At present, 38 patients have been recruited in 10 centers,
with 47 locations of oligometastases treated. 3 patients
have been evaluated at 18 months, 6 have been evaluated
at year, 4 at 9 months, 3 at 6 months, 7 at 3 months, 9
at 1 month, 2 just have been recieved SBRT now and 2 are
pending to the initial studies. 2 patients were lost in
follow-up. In all there is local and biochemical control. No
patient had symptoms related to local progression. 2
(5,5%) of them has disease progression during the follow-
up and they are being evaluated for a new SBRT. All of
them have not grade >2 toxicity related to SBRT. 9 (25%)
patients were included in a state of castration resistance
without the need to start second generation hormonal
treatment.
Conclusion
This trial presents a favorable pace of recruitment with
good initial figures of biochemical control and local
control without the appearance of remarkable SBRT
related toxicity at this time.
EP-1321 Salvage Radiotherapy in locoregional
macroscopically relapsed Prostate
cancer:retrospective analysis
A. Bruni
1
, G. Ingrosso
2
, E. Mazzeo
1
, L.M. Lamin
1
, B.
Lanfranchi
1
, M. Andolina
1
, P. Morelli
2
, I. Turturici
2
, G.
Guidi
3
, R. Santoni
2
1
AOU Policlinico of Modena, Radiation Oncology Unit,
Modena, Italy
2
Tor Vergata University General Hospital, Radiation
Oncology Unit, Rome, Italy
3
AOU Policlinico of Modena, Medical Physics Department,
Modena, Italy
Purpose or Objective
A subset of patients (pts) with Prostate Cancer (PCa)
experiences a biochemical/clinical recurrence following
radical prostatectomy (RPP). Even if Salvage Radiation
Therapy (SRT) after RPP is recommended as soon as the
PSA rises above 0.20 ng/ml, some pts experience a loco-